Aldeyra Therapeutics grants stock options to director
Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation.
Rhea-AI Filing Summary
Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation. One option for 2,323 shares of common stock and another for 70,000 shares were granted with an exercise price of $1.72 per share and an expiration date of June 8, 2036.
Each grant becomes exercisable for 100% of the underlying shares on the one-year anniversary of the grant date. Vesting is conditioned on Clark providing continuous service, respectively, as a member of the Board of Directors and of the Nominating/Corporate Governance Committee through the applicable vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 72,323 shares
Grant/Award
2 txns
Insider
Clark William D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 70,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 2,323 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 72,323 contracts (Direct)
Footnotes (2)
- F1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- F2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
Key Figures
Option grant size 1: 2,323 shares
Option grant size 2: 70,000 shares
Exercise price: $1.72 per share
+2 more
5 metrics
Option grant size 1
2,323 shares
Stock Option (Right to Buy) granted to director
Option grant size 2
70,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$1.72 per share
Conversion or exercise price for both option grants
Expiration date
June 8, 2036
Option expiration for both grants
Vesting schedule
100% after one year
Each grant vests on one-year anniversary of grant date
Key Terms
Stock Option (Right to Buy), grant/award acquisition, derivative, Nominating/Corporate Governance Committee, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
Nominating/Corporate Governance Committee financial
"service as a member of the Nominating/Corporate Governance Committee of the Board"
A nominating/corporate governance committee is a small group of a company’s board members tasked with choosing and evaluating directors and setting the rules that guide how the board operates. Think of it as the board’s hiring and rule-making team: it shapes leadership, board makeup, independence and ethical standards, which in turn influence how well the company is overseen and how investor interests are protected.
continuous service financial
"provided that the Reporting Person provides continuous service as a member"
FAQ
What insider transaction did Aldeyra Therapeutics (ALDX) disclose on this Form 4?
Aldeyra Therapeutics disclosed stock option grants to director William D. Clark. He received two option awards over common stock, reported as derivative acquisitions rather than open-market purchases, reflecting equity-based director compensation instead of cash transactions.
How many stock options did Aldeyra director William D. Clark receive?
Clark received two stock option grants: one covering 2,323 shares and another covering 70,000 shares of Aldeyra common stock. Both positions are reported as newly awarded derivative securities held directly following the transactions.
What is the exercise price of William D. Clark’s Aldeyra stock options?
Both option awards have an exercise price of $1.72 per share. This means Clark can buy Aldeyra common stock at $1.72 if and when the options vest and he chooses to exercise them before they expire.
When do William D. Clark’s Aldeyra stock options expire?
The Form 4 shows an expiration date of June 8, 2036 for each stock option grant. Clark generally must exercise any vested options on or before that date to acquire the underlying Aldeyra common shares.
What are the vesting conditions for Aldeyra director William D. Clark’s options?
Each option becomes exercisable for 100% of its shares after one year, provided Clark continues serving. One grant requires continuous service on the Board of Directors, and the other requires continuous service on the Nominating/Corporate Governance Committee through the vesting date.
Are William D. Clark’s Aldeyra option grants open-market purchases or compensation awards?
These transactions are reported with code A as a grant or award acquisition. They represent equity compensation rather than open-market buying, with no purchase price paid at grant beyond the stated future exercise price of $1.72 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
